Lupin
- Advice
- Hold
Lupin Performance
Day Range
- Low 1,224.05
- High 1,247.20
52 Week Range
- Low 628.00
- High 1,308.95
- Open Price1,239.50
- Previous Close1,239.35
- Volume621598
Start SIP in Lupin
Start SIPLupin Investment Rating
-
Master Rating:
-
Lupin (Nse) has an operating revenue of Rs. 18,604.92 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 4% needs improvement, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 32% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 74 which is a FAIR score but needs to improve its earnings, a RS Rating of 75 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 3,560 | 3,496 | 2,745 | 2,861 | 2,829 | 2,684 | 2,504 |
Operating Expenses Qtr Cr | 2,824 | 2,791 | 2,574 | 2,646 | 2,515 | 2,444 | 2,354 |
Operating Profit Qtr Cr | 835 | 705 | 262 | 215 | 314 | 289 | 501 |
Depreciation Qtr Cr | 149 | 140 | 146 | 134 | 138 | 130 | 131 |
Interest Qtr Cr | 15 | 16 | 29 | 31 | 18 | 20 | 25 |
Tax Qtr Cr | 147 | 100 | 23 | 27 | 24 | 28 | 397 |
Net Profit Qtr Cr | 549 | 477 | 119 | 40 | 149 | 117 | -36 |
Lupin Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 10
- Bearish Moving Average
- ___
- 6
- 20 Day
- ₹1,230.40
- 50 Day
- ₹1,190.69
- 100 Day
- ₹1,119.08
- 200 Day
- ₹1,008.04
- 20 Day
- ₹1,227.26
- 50 Day
- ₹1,191.97
- 100 Day
- ₹1,131.07
- 200 Day
- ₹941.17
Lupin Resistance and Support
Resistance | |
---|---|
First Resistance | 1,243.22 |
Second Resistance | 1,256.78 |
Third Resistance | 1,266.37 |
RSI | 52.48 |
MFI | 67.72 |
MACD Single Line | 21.79 |
MACD | 18.87 |
Support | |
---|---|
First Resistance | 1,220.07 |
Second Resistance | 1,210.48 |
Third Resistance | 1,196.92 |
Lupin Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 684,205 | 35,619,712 | 52.06 |
Week | 1,163,423 | 72,015,859 | 61.9 |
1 Month | 1,365,005 | 69,533,378 | 50.94 |
6 Month | 1,278,660 | 51,772,950 | 40.49 |
Lupin Result Highlights
Lupin Synopsis
NSE-Medical-Generic Drugs
Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11258.83 Cr. and Equity Capital is Rs. 91.00 Cr. for the Year ended 31/03/2023. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.Market Cap | 55,982 |
Sales | 12,852 |
Shares in Float | 24.13 |
No of funds | 627 |
Yield | 0.32 |
Book Value | 3.06 |
U/D Vol ratio | 1.2 |
LTDebt / Equity | |
Alpha | 0.18 |
Beta | 0.57 |
Lupin
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 47.06% | 47.07% | 47.08% | 47.1% |
Mutual Funds | 16.71% | 17% | 16.96% | 16.47% |
Insurance Companies | 12.26% | 11.84% | 11.73% | 11.39% |
Foreign Portfolio Investors | 14.99% | 13.93% | 13.32% | 13.98% |
Financial Institutions/ Banks | 0.14% | 0.14% | 0.14% | 0.14% |
Individual Investors | 6.24% | 7.06% | 7.86% | 8.06% |
Others | 2.6% | 2.96% | 2.91% | 2.86% |
Lupin Management
Name | Designation |
---|---|
Mrs. Manju D Gupta | Chairman |
Mr. Nilesh D Gupta | Managing Director |
Mr. Ramesh Swaminathan | Executive Director & Global CFO |
Ms. Vinita Gupta | Director & CEO |
Mr. Jean-Luc Belingard | Independent Director |
Mr. K B S Anand | Independent Director |
Dr. Punita Kumar-Sinha | Independent Director |
Mr. Mark D McDade | Independent Director |
Lupin Forecast
Price Estimates
Lupin Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-08 | Quarterly Results | |
2023-08-03 | Quarterly Results | |
2023-05-09 | Audited Results & Final Dividend | |
2023-02-09 | Quarterly Results | |
2022-11-09 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2023-07-14 | FINAL | Rs.4.00 per share (200%)Final Dividend |
2022-07-15 | FINAL | Rs.4.00 per share(200%)Final Dividend |
2021-07-28 | FINAL | Rs.6.50 per share(325%)Final Dividend |
About Lupin
Lupin FAQs
What is Share Price of Lupin ?
Lupin share price is ₹1,229 As on 11 December, 2023 | 18:30
What is the Market Cap of Lupin ?
The Market Cap of Lupin is ₹55984.6 Cr As on 11 December, 2023 | 18:30
What is the P/E ratio of Lupin ?
The P/E ratio of Lupin is 42.1 As on 11 December, 2023 | 18:30
What is the PB ratio of Lupin ?
The PB ratio of Lupin is 4.5 As on 11 December, 2023 | 18:30
What were the company's reported sales and net income in 2022?
For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.
What is the future of Lupin Limited's shares?
Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.
How to buy Lupin’s shares?
You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.